Cervical HPV infection and neoplasia in a large population-based prospective study: The Manchester cohort

British Journal of Cancer

Volumn 91, Issue 5, 2004, Pages 942-953

  Peto, J ^a,b   Gilham, C ^b   Deacon, J ^b   Taylor, C ^b   Evans, C ^b   Binns, W ^c   Haywood, M ^d   Elanko, N ^e   Coleman, D ^f   Yule, R ^g   Desai, M ^g  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c LIVERPOOL WOMEN S HOSPITAL   (United Kingdom)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

^e ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^f Faculty of Medicine   (United Kingdom)

^g MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Cervical neoplasia; Cervical screening; CIN3; Cohort study; HPV

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER SCREENING; COHORT ANALYSIS; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PREVALENCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; UNITED KINGDOM; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; WART VIRUS;

ADOLESCENT; ADULT; AGE FACTORS; AGED; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; FEMALE; GREAT BRITAIN; HUMANS; MASS SCREENING; MIDDLE AGED; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POLYMERASE CHAIN REACTION; PREVALENCE; PROSPECTIVE STUDIES; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS; VAGINAL SMEARS;

EID: 4644318526     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602049     Document Type: Article

References (36)

1. Arbyn M, Buntinx F, Van Ranst M, Paraskevaidis E, Martin-Hirsch P, Dillner J (2004) Virologic versus cytologic triage of women with equivocal Pap smears: a meta-analysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 96: 280-293
2. Bauer H, Greer C, Manos M (1992) Determination of genital human papillomavirus infection by consensus PCR amplification. In Diagnostic Molecular Pathology: A Practical Approach, Herrington C, McGee J (eds) pp 131-152, Oxford: Oxford University Press
3. Castle PE, Schiffman M, Gravitt PE, Kendall H, Fishman S, Dong H, Hildesheim A, Herrero R, Bratti MC, Sherman ME, Lorincz A, Schussler JE, Burk RD (2002) Comparisons of HPV DNA detection by MY09/11 PCR methods. J Med Virol 68: 417-423
4. Cox JT, Schiffman M, Solomon D (2003) Prospective follow-up suggests similar risk of subsequent cervical intraepithelial neoplasia grade 2 or 3 among women with cervical intraepithelial neoplasia grade 1 or negative colposcopy and directed biopsy. Am J Obstet Gynecol 188: 1406-1412
5. Cuzick J, Szarewski A, Cubie H, Hulman G, Kitchener H, Luesley D, McGoogan E, Menon U, Terry G, Edwards R, Brooks C, Desai M, Gie C, Ho L, Jacobs I, Pickles C, Sasieni P (2003) Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 362: 1871-1876
6. Cuzick J, Szarewski A, Terry G, Ho L, Hanby A, Maddox P, Anderson M, Kocjan G, Steele ST, Guillebaud J (1995) Human papillomavirus testing in primary cervical screening. Lancet 345: 1533-1536
7. Deacon JM, Evans CD, Yule R, Desai M, Binns W, Taylor C, Peto J (2000) Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort. Br J Cancer 83: 1565-1572
8. Evans MF, Cooper K (2004) Human papillomavirus integration: detection by in situ hybridization and potential clinical application. J Pathol 202: 1-4
9. Forsmo S, Jacobsen BK, Stalsberg H (1996) Cervical neoplasia in pap smears: risk of cervical intra-epithelial neoplasia (CIN) after negative or no prior smears in a population without a mass screening programme. Int J Epidemiol 25: 53-58
10. Herrero R, Hildesheim A, Bratti C, Sherman ME, Hutchinson M, Morales J, Balmaceda I, Greenberg MD, Alfaro M, Burk RD, Wacholder S, Plummer M, Schiffman M (2000) Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 92: 464-474
11. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, Scott DR, Rush BB, Lawler P, Sherman ME, Kurman RJ, Manos MM (1994) Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 169: 235-240
12. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD (1998) Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338: 423-428
13. Kitchener H, Wheeler P, Desai M, Corbitt G, Roberts C, Maguire P, Fletcher I, Dowie R, Moss S, Gilham C, Peto J (2004) The ARTISTIC trial - a randomised trial in screening to improve cytology (abstract 268). 21st International Papillomavirus Conference, Mexico City, pp 219
14. Kjaer SK, van den Brule AJ, Paull G, Svare EI, Sherman ME, Thomsen BL, Suntum M, Bock JE, Poll PA, Meijer CJ (2002) Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. Br Med J 325: 572
15. Koss LG, Stewart F, Foote FW, Jordan MJ, Bader GM, Day E (1963) Some histological aspects of behavior of epidermoid carcinoma in situ and related lesions of the uterine cervix. a long-term prospective study. Cancer 16: 1160-1211
16. Liaw KL, Glass AG, Manos MM, Greer CE, Scott DR, Sherman M, Burk RD, Kurman RJ, Wacholder S, Rush BB, Cadell DM, Lawler P, Tabor D, Schiffman M (1999) Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst 91: 954-960
17. Lorincz AT, Reid R, Jenson AB, Greenberg MD, Lancaster W, Kurman RJ (1992) Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types. Obstet Gynecol 79: 328-337
18. Manos M, Wright D, Lewis A, Broker T, Wolinsky S (1989) The use of PCR amplification for the detection of genital HPVs. In Molecular Diagnostics of Human Cancer, Cancer Cells 7, Furth M, Greaves M (eds) pp 209-214, Cold Spring Harbor, NY: Cold Spring Harbor Press
19. Miller AB (2002) The (in)efficiency of cervical screening in Europe. Eur J Cancer 38: 321-326
20. Nobbenhuis MA, Helmerhorst TJ, van den Brule AJ, Rozendaal L, Voorhorst FJ, Bezemer PD, Verheijen RH, Meijer CJ (2001) Cytological regression and clearance of high-risk human papillomavirus in women with an abnormal cervical smear. Lancet 358: 1782-1783
21. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, van der Linden HC, Voorhorst FJ, Kenemans P, Meijer CJ (1999) Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer screening: a prospective study. Lancet 354: 20-25
22. Noller KL, Bettes B, Zinberg S, Schulkin J (2003) Cervical cytology screening practices among obstetrician-gynecologists. Obstet Gynecol 102: 259-265
23. Peto J, Gilham C, Fletcher O, Matthews F (2004) The cervical cancer epidemic that screening has prevented in the UK. Lancet 364: 249-256
24. Remmink AJ, Walboomers JM, Helmerhorst TJ, Voorhorst FJ, Rozendaal L, Risse EK, Meijer CJ, Kenemans P (1995) The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive disease: natural history up to 36 months. Int J Cancer 61: 306-311
25. Sasieni P, Cuzick J (2001) Routine audit is an ethical requirement of screening. Br Med J 322: 1179
26. Sawaya GF, McConnell KJ, Kulasingam SL, Lawson HW, Kerlikowske K, Melnikow J, Lee NC, Gildengorin G, Myers ER, Washington AE (2003) Risk of cervical cancer associated with extending the interval between cervical-cancer screenings. N Engl J Med 349: 1501-1509
27. Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL, Franco EL (2001) Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 286: 3106-3114
28. Sherman ME (2003) Chapter 11: Future directions in cervical pathology. J Natl Cancer Inst Monogr 31: 72-79
29. Sherman ME, Lorincz AT, Scott DR, Wacholder S, Castle PE, Glass AG, Mielzynska-Lohnas I, Rush BB, Schiffman M (2003) Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 95: 46-52
30. Sigurdsson K, Adalsteinsson S (2001) Risk variables affecting high-grade Pap smears at second visit: effects of screening interval, year, age and low-grade smears. Int J Cancer 94: 884-888
31. Solomon D, Davey D, Kurman R, Moriarty A, O'Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright Jr T, Young N (2002) The 2001 Bethesda System: terminology for reporting results of cervical cytology. JAMA 287: 2114-2119
32. Syrjanen K, Kataja V, Yliskoski M, Chang F, Syrjanen S, Saarikoski S (1992) Natural history of cervical human papillomavirus lesions does not substantiate the biologic relevance of the Bethesda System. Obstet Gynecol 79: 675-682
33. Van Ranst M, Kaplan JB, Burk RD (1992) Phylogenetic classification of human papillomaviruses: correlation with clinical manifestations. J Gen Virol 73(Part 10): 2653-2660
34. Vonka V, Kanka J, Jelinek J, Subrt I, Suchanek A, Havrankova A, Vachal M, Hirsch I, Domorazkova E, Zavadova H, Richterova V, Naprstkova J, Dvorakova J, Dvorakova V, Svoboda B (1984) Prospective study on the relationship between cervical neoplasia and herpes simplex type-2 virus. I. Epidemiological characteristics. Int J Cancer 33: 49-60
35. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19
36. Wheeler CM, Greer CE, Becker TM, Hunt WC, Anderson SM, Manos MM (1996) Short-term fluctuations in the detection of cervical human papillomavirus DNA. Obstet Gynecol 88: 261-268